April 23, 2014 — Xeltis announced it finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels.

April 23, 2014 — Philips Healthcare has completed its first field study for its Minicare handheld cardiac Troponin-I (cTn-I) blood test, demonstrating the platform’s potential to produce lab-equivalent results with finger prick samples within minutes. The initial results are encouraging as Philips prepares for the Minicare cTn-I system’s clinical trial, scheduled for 2015.


The Federal Circuit Court of Appeals granted a request from Medtronic Inc. to postpone the implementation of an injunction that would have prevented the company from selling its CoreValve System in the United States. The April 21 decision means the injunction will only take effect if the appellate court determines the injunction was properly issued.


 Loyola University Medical Center is now offering patients the most advanced positron emission tomography/computed tomography (PET/CT) scanner on the market.

Volcano Corp. announced U.S. Food and Drug Administration (FDA) clearance of its proprietary Instant Wave-Free Ratio (iFR) modality.

April 21, 2014 — Decision Resources Group announced in a report that Servier's ivabradine (procoralan) is set to become the clinical gold standard in the treatment of chronic heart failure (CHF). Already available in Europe, where it has enjoyed moderate use in CHF and stable angina patients, ivabradine's clinical profile could prime this agent for a potentially successful launch in the United States, where Amgen own the marketing rights to procoralan.

Subscribe Now